According to new data released today, the Express Scripts SafeGuardRx® offering – the company’s first-to-market value-based programs for employers and health plans – improved patient engagement and increased medication adherence while reducing costs for some of the nation’s costliest therapies.
ST. LOUIS, March 27, 2019 /PRNewswire/ -- According to new data released today, the Express Scripts SafeGuardRx® offering – the company’s first-to-market value-based programs for employers and health plans – improved patient engagement and increased medication adherence while reducing costs for some of the nation’s costliest therapies. The SafeGuardRx® program combines innovative reimbursement strategies with novel clinical initiatives to help plans and patients derive the most value in high-cost therapy classes, such as inflammatory conditions, oncology and diabetes. Express Scripts tailors each program to address the unique characteristics and challenges of the therapy class to ensure the greatest value returned. Better Engagement, Better Adherence, Better Access In our Diabetes Care ValueSM program we:
Additionally, our Pulmonary Care ValueSM program reduced rescue inhaler use among people with asthma or COPD by 72 percent in 2018 through the use of remote monitoring technology, which allows for a pulmonary specialist pharmacist to engage with a patient after observing increased rescue inhaler. In addition to improved quality of life, reduced rescue inhaler use means a patient’s condition is better controlled and is less likely to require medical intervention at an ER or hospital. Through our Cholesterol Care ValueSM program, members gained more simplified access to the PCSK9 inhibitor Praluent®. The program also reduced individuals’ out-of-pocket costs through the point-of-sale rebates we introduced in July 2018, resulting in as much as $319 in direct per member, per prescription savings. “Innovations in medicine that deliver potentially break-through treatments but have exorbitant prices require equally innovative reimbursement solutions that ensure value for plans and patients,” said Candice Michaelson, Vice President, Value Based Solutions, Express Scripts. “Year after year with SafeGuardRx, we have proven that although healthcare is dynamic and complex, we can deliver to plans and patients a sustainable way to make these high-cost therapies accessible and affordable, and ensure patients achieve the greatest value possible.” Sustainable Benefits for Plan Sponsors The unique indication-based reimbursement design of the Inflammatory Conditions Care ValueSM program – which allows for additional competition to make the therapy class more affordable by shifting market share from market-dominating therapies to other effective medications – is the driving factor in the decreased spending for plans enrolled in the program. Overall, drug spending in SafeGuardRx programs focused on traditional therapy classes, such as pulmonary conditions and diabetes, was 18 percent less for enrolled plans compared to non-enrolled plans in 2018. For SafeGuardRx programs focused on specialty therapy classes, spending was 5 percent less for enrolled plans compared to non-enrolled plans. About SafeGuardRx About Express Scripts We stand alongside our clients and partners, collaborating to develop personalized solutions that make a meaningful difference in the lives of those we serve, whenever and wherever it’s needed. We believe health care can do more. We are Champions For BetterSM. Express Scripts, part of Cigna, unlocks new value in pharmacy, medical, and beyond to further total health for all. All trademarks are the property of their respective owners. Media Contact:
View original content to download multimedia:http://www.prnewswire.com/news-releases/express-scripts-data-shows-value-based-programs-deliver-better-health-affordability-for-costly-conditions-300819263.html SOURCE Express Scripts |